CAJ | 학술논문

目的：观察肾康宁方治疗早期糖尿病肾病（ DN）的临床疗效。方法将120例DN患者随机分为2组。2组均予以常规治疗，治疗组60例加服肾康宁方，对照组加服马来酸依那普利片。2组疗程均为8周。观察2组治疗前后尿白蛋白排泄率（ UAER）、血清肿瘤坏死因子-α（ TNF-α）、胰岛素样生长因子-1（IGF-1）及血糖、血脂、血液流变学等变化。结果治疗组总有效率81．67％，对照组总有效率63．33％，2组比较差异有统计学意义（P＜0．05），治疗组疗效优于对照组；2组治疗后空腹血糖（FPG）、餐后2 h血糖（2 hPG）及糖化血红蛋白（HbAlc）均下降（P＜0．01）；治疗组治疗后UAER、TNF-α、IGF-1、胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、全血黏度（高切、低切）、血浆黏度、红细胞聚集指数均下降（P＜0．05，P＜0．01），与对照组比较差异均有统计学意义（ P ＜0．05， P＜0．01）。结论肾康宁方可降低早期 DN患者UAER、TNF-α及IGF-1水平，改善血脂和血液黏稠度，有效防治早期DN。
목적：관찰신강저방치료조기당뇨병신병（ DN）적림상료효。방법장120례DN환자수궤분위2조。2조균여이상규치료，치료조60례가복신강저방，대조조가복마래산의나보리편。2조료정균위8주。관찰2조치료전후뇨백단백배설솔（ UAER）、혈청종류배사인자-α（ TNF-α）、이도소양생장인자-1（IGF-1）급혈당、혈지、혈액류변학등변화。결과치료조총유효솔81．67％，대조조총유효솔63．33％，2조비교차이유통계학의의（P＜0．05），치료조료효우우대조조；2조치료후공복혈당（FPG）、찬후2 h혈당（2 hPG）급당화혈홍단백（HbAlc）균하강（P＜0．01）；치료조치료후UAER、TNF-α、IGF-1、담고순（TC）、저밀도지단백담고순（LDL-C）、전혈점도（고절、저절）、혈장점도、홍세포취집지수균하강（P＜0．05，P＜0．01），여대조조비교차이균유통계학의의（ P ＜0．05， P＜0．01）。결론신강저방가강저조기 DN환자UAER、TNF-α급IGF-1수평，개선혈지화혈액점주도，유효방치조기DN。
Objective To observe the clinical effect of early diabetic nephropathy ( DN) treated by Shen-kangning prescription .Methods 120 DN patients were randomly divided into two groups .The cases in two groups were treated by conventional therapy .60 cases in treatment group received Shenkangning prescription .60 cases in con-trol group received Enalapril .The course was eight weeks in two groups .The changes of UAER ,TNF-α,IGF-1, blood lipid and hemorheology before and after treatment were observed in two groups .Results The total effective rate in treatment group(81.67%) was superior to that in control group (63.33%,P<0.05).UAER,TNF-α,IGF-1,TC,LDL -C,whole blood viscosity,plasma viscosity and erythrocyte aggregation index after treatment were de-creased in treatment group(P<0.05,P<0.01).There were significant differences between two groups on UAER , TNF-α,IGF-1,TC,LDL-C,whole blood viscosity ,plasma viscosity and erythrocyte aggregation index ( P<0.05, P<0.01).Conclusion Shenkangning prescription can decrease the levels of UARE ,TNF-αand IGF-1 in pa-tients with early diabetic nephropathy ,improve blood lipid and blood viscosity and effectively protect and treat early diabetic nephropathy .